ReviewCancers2018
Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer.
Review in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- All the Way: A Decade of SIRT1 in Breast Cancer.Biomedicines · 2026Review
- Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies.Journal of enzyme inhibition and medicinal chemistry · 2025Article
- Arzanol: A Review of Chemical Properties and Biological Activities.Plants (Basel, Switzerland) · 2025Review
- Review
- Targeting NAD Metabolism: Rational Design, Synthesis and In Vitro Evaluation of NAMPT/PARP1 Dual-Target Inhibitors as Anti-Breast Cancer Agents.Molecules (Basel, Switzerland) · 2024Article
- SIRT1 regulates DNA damage signaling through the PP4 phosphatase complex.Nucleic acids research · 2023Article
- The prognostic implications of SIRTs expression in breast cancer: a systematic review and meta-analysis.Discover oncology · 2022Article
- Therapeutic potential of anti-miR29a in breast cancer patients with type 2 diabetes: anTranslational cancer research · 2022Article
- Adiponectin triggers breast cancer cell death via fatty acid metabolic reprogramming.Journal of experimental & clinical cancer research : CR · 2022Article
- Anticancer activity of N-heteroaryl acetic acid salts against breast cancer; in silico and in vitro investigation.Molecular biology reports · 2022Article
- Dysregulation and activities of ubiquitin specific peptidase 2b in the pathogenesis of hepatocellular carcinoma.American journal of cancer research · 2021Article
- Circular and linear: a tale of aptamer selection for the activation of SIRT1 to induce death in cancer cells.RSC advances · 2020Article
- Biochemical mechanism and biological effects of the inhibition of silent information regulator 1 (SIRT1) by EX-527 (SEN0014196 or selisistat).Journal of enzyme inhibition and medicinal chemistry · 2020Article
- 2-Hydroxyglutarate in Cancer Cells.Antioxidants & redox signaling · 2020Review
- The Role of Nicotinamide in Cancer Chemoprevention and Therapy.Biomolecules · 2020Review
- SIRT6 is a DNA double-strand break sensor.eLife · 2020Article
- Sirtuin 1 Inhibiting Thiocyanates (S1th)-A New Class of Isotype Selective Inhibitors of NADFrontiers in oncology · 2020Article
- Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials.Frontiers in genetics · 2020Review
- SRC Promotes Tamoxifen Resistance in Breast Cancer via Up-Regulating SIRT1.OncoTargets and therapy · 2020Article
- Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.Molecular therapy oncolytics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most common type of cancer in women worldwide; it is a multifactorial genetic disease. Acetylation and deacetylation are major post-translational protein modifications that regulate gene expression and the activity of a myriad of oncoproteins. Aberrant deacetylase activity can promote or suppress tumorigenesis and cancer metastasis in different types of human cancers, including breast cancer. Sirtuin-1 (SIRT1) is a class-III histone deacetylase (HDAC) that deacetylates both histone and non-histone targets. The often-described 'regulator of regulators' is deeply implicated in apoptosis, gene regulation, genome maintenance, DNA repair, aging, and cancer development. However, despite the accumulated studies over the past decade, the role of SIRT1 in human breast cancer remains a subject of debate and controversy. The ambiguity surrounding the implications of SIRT1 in breast tumorigenesis stems from the discrepancy between studies, which have shown both tumor-suppressive and promoting functions of SIRT1. Furthermore, studies have shown that SIRT1 deficiency promotes or suppresses tumors in breast cancer, making it an attractive therapeutic target in cancer treatment. This review provides a comprehensive examination of the various implications of SIRT1 in breast cancer development and metastasis. We will also discuss the mechanisms underlying the conflicting roles of SIRT1, as well as its selective modulators, in breast carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.